Trifluridine, Tipiracil — Drug Intelligence | 10 EU Trials

Filter these 10 trials by condition, phase, country and more.

Open in Search →

10 Registered trials

5 Recruiting

5 Completed trials

8 Sponsors

12 Countries

Phase III

Phase II/III

Phase II

Phase III: 5 Phase II/III: 1 Phase II: 4

Oversight events:

1 corrective measure across 1 trial

View oversight register →

Indications tested

Colon cancer 1 Colorectal cancer metastatic 1 Colorectal cancer 1 Colon cancer metastatic 1

Sponsors using this IMP

Merck Sharp & Dohme LLC 2 Unicancer 2 AbbVie Deutschland GmbH & Co. KG 1 Agenus Inc. 1 AstraZeneca AB 1 Centre Hospitalier Universitaire De Dijon 1 Delcath Systems Inc. 1 Universitaetsklinikum Heidelberg AöR 1

All trials

10 total

A study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination with IV Bevacizumab Compared to Standard of Care IV Bevacizumab i… Recruiting

2025-521712-19-00 Phase III 5 countries AbbVie Deutschland GmbH & Co. KG
Randomized Study to Evaluate Melphalan/HDS Treatment Followed by Trifluridine–tipiracil plus Bevacizumab Versus Trifluridine–tipiracil plus … Recruiting

2024-520356-24-00 Phase II 5 countries Delcath Systems Inc.
PRODIGE 88-CIRCULATE PAC: Phase III multicentric, open-label, randomized study to investigate the efficacy of chemotherapy in patients with … Recruiting

2023-505046-26-00 Phase III 1 country Centre Hospitalier Universitaire De Dijon
Safety of Trifluridine/tipiracil in patients with dihydropyrimidine dehydrogenase deficiency diagnosed with metastatic colorectal or gastroe… Recruiting

2023-508724-35-00 Phase II 1 country Unicancer
Oxaliplatin ± nivolumab in combination with trifluridine/tipiracil or 5- fluorouracile ± nivolumab in frail patients with advanced, recurren… Recruiting

2024-512999-35-00 Phase II 1 country Unicancer
A trial to learn how well AZD0901 works and how safe it is compared to standard cancer treatments in adults with advanced and metastatic gas… Ended

2023-508276-11-00 Phase III 5 countries AstraZeneca AB
A clinical study of MK-2870 in people with stomach cancer (MK-2870-015) Ended

2023-505423-31-00 Phase III 7 countries Merck Sharp & Dohme LLC
Clinical study to investigate efficacy of Botensilimab (AGEN1181) as Monotherapy and in Combination with Balstilimab (AGEN2034) or Investiga… Ended

2022-502065-23-00 Phase II 4 countries Agenus Inc.
A randomized, open label, multicenter phase II/III trial of sacituzumab govitecan compared to standard of care in metastatic, refractory col… Ended

2023-509771-17-00 Phase II/III 1 country Universitaetsklinikum Heidelberg AöR
Clinical trial of MK-4280A for colorectal cancer that has spread after previous treatment Ended

2024-511043-25-00 Phase III 4 countries Merck Sharp & Dohme LLC

Showing 1–10 of 10 trials

← All drugs A–Z